{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009124","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.733479+00:00","generated_at":"2026-06-25T20:43:56.754544+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q1 core lung diag rev $4.6M (+17% YoY); net loss $15.6M; raised $27.4M post-quarter","bullets":["Core lung diagnostic revenue $4.6M (+17% YoY); total revenue $6.5M (-77% YoY) as COVID-19 testing fell 96%.","Net loss $15.6M (increase 124% YoY); operating expenses $17.8M, up 10%.","Raised $27.4M post-Q1: $11.7M private placement, $2.7M ATM, $13M net from $25M debt facility.","Restructured Indi milestone payments, reducing 2022 pay by $7.5M and 2023 by $7.2M.","Reaffirmed FY2022 total revenue outlook of $37.5M-$39.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009124","json":"https://secwatch.observer/filing/0000950170-22-009124.json","markdown":"https://secwatch.observer/filing/0000950170-22-009124.md","text":"https://secwatch.observer/filing/0000950170-22-009124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022009124/0000950170-22-009124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017022009124/bdsx-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:43:56.754544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}